ReviewClinical reviews in allergy & immunology2020
Asthma Phenotypes as a Guide for Current and Future Biologic Therapies.
Review in Clinical reviews in allergy & immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- MARCKS protein is a potential target in a naturally occurring equine model of neutrophilic asthma.Respiratory research · 2025Article
- Clinical Utility of Central and Peripheral Airway Nitric Oxide in Children with Different Types of Allergic Asthma.Journal of asthma and allergy · 2025Article
- Emerging Role and Function of Th9 Cells in Allergic Inflammation.Journal of inflammation research · 2025Review
- The potential immunomodulatory role of human milk oligosaccharides in prevention of viral infections and development of asthma in early life.Frontiers in immunology · 2025Review
- CTSS contributes to airway neutrophilic inflammation in mixed granulocytic asthma.Respiratory research · 2024Article
- Review
- Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum.International journal of molecular sciences · 2024Article
- Unraveling heterogeneity and treatment of asthma through integrating multi-omics data.Frontiers in allergy · 2024Review
- PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Maternal asthma in relation to infant size and body composition.The journal of allergy and clinical immunology. Global · 2023Article
- Airway Epithelium: A Neglected but Crucial Cell Type in Asthma Pathobiology.Diagnostics (Basel, Switzerland) · 2023Review
- Gene network analysis for identification of microRNA biomarkers for asthma.Respiratory research · 2022Article
- Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response.ImmunoHorizons · 2022Article
- The NLRP3 inflammasome as a new target in respiratory disorders treatment.Frontiers in immunology · 2022Review
- Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma.Frontiers in immunology · 2022Article
- Purified Native and Recombinant MajorJournal of fungi (Basel, Switzerland) · 2021Article
- A probiotic has differential effects on allergic airway inflammation in A/J and C57BL/6 mice and is correlated with the gut microbiome.Microbiome · 2021Article
- Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study.Medicine · 2021Observational
- T2-high Asthma, Classified by Sputum mRNA Expression ofLife (Basel, Switzerland) · 2021Article
- The impact of 17β-estradiol and progesterone therapy on peripheral blood mononuclear cells of asthmatic patients.Molecular biology reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma has been increasingly recognized as being a heterogeneous disease with multiple distinct mechanisms and pathophysiologies. Evidence continues to build regarding the existence of different cell types, environmental exposures, pathogens, and other factors that produce a similar set of symptoms known collectively as asthma. This has led to a movement from a "one size fits all" symptom-based methodology to a more patient-centered, individualized approach to asthma treatment targeting the underlying disease process. A significant contributor to this shift to more personalized asthma therapy has been the increasing availability of numerous biologic therapies in recent years, providing the opportunity for more targeted treatments. When targeted biologics began to be developed for treatment of asthma, the hope was that distinct biomarkers would become available, allowing the clinician to determine which biologic therapy was best suited for which patients. Presence of certain biomarkers, like eosinophilia or antigen-specific IgE, is important features of specific asthma phenotypes. Currently available biomarkers can help with decision making about biologics, but are generally too broad and non-specific to clearly identify an asthma phenotype or the single biologic best suited to an asthmatic. Identification of further biomarkers is the subject of intense research. Yet, identifying a patient's asthma phenotype can help in predicting disease course, response to treatment, and biologic therapies to consider. In this review, major asthma phenotypes are reviewed, and the evidence for the utility of various biologics, both those currently on the market and those in the development process, in each of these phenotypes is explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.